Humana Inc. announced the expansion of its validated science-based target (SBT) with recent approval of a new financial institution target by the Science Based Targets initiative (SBTi). This milestone highlights Humana's dedication to sustainability, reinforcing its commitment to improving health and well-being while aiming for significant emissions reductions across the company's value chain. The following outlines Humana's Scope 3 asset class level target, emphasizing commitment to sustainable investment practices and alignment with SBTi-validated goals.
Asset class Method Target language: Listed equity and Portfolio Coverage: Humana commits to 67.3% of its listed equity and corporate bond portfolio by invested value setting corporate bonds SBTi-validated targets by 2029 from a 2022 base year. This complements the company's existing targets covering the rest of its value chain, including a commitment to reduce absolute Scope 3 emissions from purchased goods and services, as well as upstream transportation and distribution, by 30% by 2032 from a 2022 base year. The newly approved target for Scope 3, Category 15 financed emissions refer to the indirect greenhouse gas emissions from investments and lending activities.
To achieve the financed emissions target, Humana has revised its investment policy to incorporate SBTi-aligned climate commitments. These proactive measures highlight Humana's commitment to fostering healthier environments for its members, patients, employees, and communities, and aligns its financial influence with its operational impact. Humana's Scope 1 and 2 targets, approved in 2023, remain unchanged and continue to align with limiting global temperature rise.
The company's science-based targets and 1.5degC trajectory are designed to spur innovation and efficiency demonstrating ongoing leadership in climate action within the healthcare and insurance sectors, boost investor confidence and position Humana to support a broader decarbonization effort across its value chain and financial ecosystem.
